<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093517</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20210463H</org_study_id>
    <nct_id>NCT05093517</nct_id>
  </id_info>
  <brief_title>Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM</brief_title>
  <official_title>Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With REMD's glucagon receptor antagonist, the study team propose to provide a comprehensive&#xD;
      examination of the effect of elevated plasma glucagon concentrations in Type 2 Diabetes&#xD;
      Mellitus (T2D) patients on:&#xD;
&#xD;
      (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta&#xD;
      cell function; (iv) adipocyte inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with T2DM inadequately controlled on current medications will participate in a&#xD;
      glucose tolerance test, euglycemic insulin clamp combined with 3-3H-glucose and 14-C glycerol&#xD;
      infusion, adipose tissue biopsy, before and 12 weeks after treatment with REMD 477 or&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized 2-arm placebo controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded to the study drug or placebo randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Glycated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in HbA1c measured at baseline and after intervention administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting Plasma glucose (FPG)</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in fasting plasma glucose measured at baseline and after intervention administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose (PG)</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in plasma PG measured at baseline and after intervention administration using an oral glucose tolerance test (OGTT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic insulin sensitivity</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in hepatic glucose production (HGP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole body glucose disposal</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in whole body glucose disposal measured in mg/kg/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Free Fatty Acids (FFA)</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in plasma free fatty acids</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Insulin sensitivity</measure>
    <time_frame>Baseline to 13 weeks</time_frame>
    <description>Change in muscle insulin sensitivity measured by insulin-stimulated glucose uptake during low dose high dose insulin clamp.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Glucose Tolerance Impaired</condition>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Glucagon Receptor Agonist (GRA) REMD-477 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are assigned to a 12 week treatment of REMD-477</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants are assigned to a 12 week course of placebo for REMD-477</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REMD-477</intervention_name>
    <description>A biologic glucagon receptor agonist to which randomized subjects are assigned 2:1</description>
    <arm_group_label>Glucagon Receptor Agonist (GRA) REMD-477 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Subcutaneous injection</intervention_name>
    <description>Placebo for REMD-477 to which subjects will be randomized 1:2.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 2 diabetic subjects, males/females;&#xD;
&#xD;
          2. age = 18-70 years&#xD;
&#xD;
          3. BMI = 25-40 kg/m2;&#xD;
&#xD;
          4. HbA1c = 7.5-10.0%;&#xD;
&#xD;
          5. Type 2 Diabetics who are drug naïve or treated with metformin, sulfonylureas, SGLT-2&#xD;
             inhibitors or any combination thereof.&#xD;
&#xD;
          6. Subjects must be on a stable dose of antidiabetic medications for at least 3 months&#xD;
             prior to study.&#xD;
&#xD;
          7. Patients must be able to communicate meaningfully with the investigator and must be&#xD;
             legally competent to provide written informed consent.&#xD;
&#xD;
          8. Female patients must be non-lactating and must either be at least two years&#xD;
             post-menopausal, or be using adequate contraceptive precautions (i.e. oral&#xD;
             contraceptives, approved hormonal implant, intrauterine device, diaphragm with&#xD;
             spermicide, condom with spermicide), or be surgically sterilized (i.e. bilateral tubal&#xD;
             ligation, bilateral oophorectomy). Female patients who have undergone a hysterectomy&#xD;
             are eligible for participation in the study. Female patients (except for those&#xD;
             patients who have undergone a hysterectomy or a bilateral oophorectomy) are eligible&#xD;
             only if they have a negative pregnancy test throughout the study period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a personal or family history of pancreatic neuroendocrine tumors or&#xD;
             multiple endocrine neoplasia, due to the potential increased of pancreatic alpha cell&#xD;
             carcinogenicity associated with glucagon receptor antagonists.&#xD;
&#xD;
          2. Subjects with a contraindication to MRI including artificial heart valves or&#xD;
             pacemakers&#xD;
&#xD;
          3. Patients with a known sensitivity to humanized antibodies&#xD;
&#xD;
          4. Subjects treated with GLP-1 RAs or insulin are excluded.&#xD;
&#xD;
          5. Subjects treated with a non-antidiabetic medication that may impact insulin&#xD;
             sensitivity, such as systemic steroids, or lipase inhibitors (orlistat, Alli or&#xD;
             Xenical)&#xD;
&#xD;
          6. Hematocrit &lt; 34 vol%&#xD;
&#xD;
          7. Serum creatinine &gt; 1.8 mg/dl&#xD;
&#xD;
          8. AST (SGOT) &gt; 2 times upper limit of normal&#xD;
&#xD;
          9. ALT (SGPT) &gt; 2 times upper limit of normal&#xD;
&#xD;
         10. Any major organ system disease as identified by medical history, physical exam, and&#xD;
             screening blood tests, EKG&#xD;
&#xD;
         11. Subjects who cannot give written, voluntary consent&#xD;
&#xD;
         12. Subjects with a major psychiatric disturbance&#xD;
&#xD;
         13. Only subjects whose body weight has been stable (±3-4 pounds) over the three months&#xD;
             prior to study will be included.&#xD;
&#xD;
         14. Patients must not have type 1 diabetes&#xD;
&#xD;
         15. Patients must not have a fasting plasma glucose of greater than 270 mg/dl or HbA1c &gt;&#xD;
             10.0%&#xD;
&#xD;
         16. Patients must not have received a thiazolidinedione, GLP-1 agonist, or insulin for&#xD;
             more than one week during the year prior to randomization&#xD;
&#xD;
         17. Patients with a history of clinically significant heart disease (New York Heart&#xD;
             Classification greater than class 2; more than non-specific ST-T wave changes on the&#xD;
             EKG), peripheral vascular disease (history of claudication), or pulmonary disease&#xD;
             (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation)&#xD;
             will not be studied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph DeFronzo, MD</last_name>
    <phone>210-567-6691</phone>
    <email>defronzo@uthscsa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Devjit Tripathy, MD PhD</last_name>
    <phone>210-567-6691</phone>
    <email>tripathy@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Stephen Chen, MD PhD</last_name>
      <phone>210-567-6701</phone>
      <email>Chenx8@uthsca.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph A DeFronzo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fasting plasma glucagon</keyword>
  <keyword>Glucagon receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Volagidemab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Summary results will be published in ClinicalTrials.gov as required by law and research findings will be published in a peer reviewed scientific journal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Once the study has completed enrollment and data analysis is complete, data will become available.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

